Metformin versus Insulin for the Treatment of Gestational Diabetes
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is a logical treatment for women with gestational diabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking. METHODS: We randomly assigned 751 women with gestational diabetes mellitus at 20 to 33 weeks of gestation to open treatment with metformin (with supplemental insulin if required) or insulin. The primary outcome was a composite of neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute Apgar score less than 7, or prematurity. The trial was designed to rule out a 33% increase (from 30% to 40%) in this composite outcome in infants of women treated with metformin as compared with those treated with insulin. Secondary outcomes included neonatal anthropometric measurements, maternal glycemic control, maternal hypertensive complications, postpartum glucose tolerance, and acceptability of treatment. RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. The rate of the primary composite outcome was 32.0% in the group assigned to metformin and 32.2% in the insulin group (relative risk, 0.99 [corrected]; 95% confidence interval, 0.80 [corrected] to 1.23 [corrected]). More women in the metformin group than in the insulin group stated that they would choose to receive their assigned treatment again (76.6% vs. 27.2%, P<0.001). The rates of other secondary outcomes did not differ significantly between the groups. There were no serious adverse events associated with the use of metformin. CONCLUSIONS: In women with gestational diabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin. The women preferred metformin to insulin treatment. (Australian New Zealand Clinical Trials Registry number, 12605000311651.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While individual RCTs support limited efficacy of metformin (73,74) and glyburide (75) in reducing glucose levels for the treatment of GDM, these agents are not recommended as the first-line treatment for GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (35).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [73]
In the citing paper
“It was concluded that metformin alone, or with supplemental insulin, was not associated with increased perinatal complications.”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [112]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [89]
In the citing paper
“Glyburide is effective in controlling blood glucose in women with gestational diabetes”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Dabelea, D., Hanson, R. L., Lindsay, R. S., Pettitt, D. J., Imperatore, G., Gabir, M. M., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2208 · Cited by 1,277
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924
Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes
Ben‐Haroush, A., Yogev, Y., & Hod, M. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00985.x · Cited by 856
Gestational diabetes: The consequences of not treating
Langer, O., Yogev, Y., Most, O., & Xenakis, E. M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.11.039 · Cited by 677
Silverman, B. L., Metzger, B. E., Cho, N. H., & Loeb, C. A. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.611 · Cited by 643
Hoffman, L., Nolan, C., Wilson, J. D., Oats, J. J. N., & Simmons, D. (1998) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb140192.x · Cited by 570
An Increase in the Incidence of Gestational Diabetes Mellitus: Northern California, 1991–2000
Ferrara, A., Kahn, H. S., Quesenberry, C. P., Riley, C., & Hedderson, M. M. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000113623.18286.20 · Cited by 452
Glueck, C. J., Phillips, H., Cameron, D., Sieve-Smith, L., & Wang, P. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01666-6 · Cited by 430
Research works printed but not linked: 3
- Coetzee EJ, 1980, S Afr Med J, 58, 795
- Coetzee EJ, 1984, S Afr Med J, 65, 635
- Gutzin SJ, 2003, Can J Clin Pharmacol, 10, 179
Cited by
Items 101–200 of 1,001
Experiences of gestational diabetes and gestational diabetes care: a focus group and interview study
Parsons, J., Sparrow, K., Ismail, K., Hunt, K., Rogers, H., & Forbes, A. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-1657-9 · Cited by 132
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 171
Metformin use in pregnancy: promises and uncertainties
Lindsay, R. S., & Loeken, M. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4351-y · Cited by 127
“Diabetes (MiG) randomised clinical trial by Rowan et al in 2008 altered medical practice in many countries [14].”
BackgroundMethodTaylor, B., Woodfall, G., Sheedy, K., O’Riley, M., Rainbow, K., Bramwell, E., & Kellow, N. (2017) · Nutrients · doi:10.3390/nu9050461 · Cited by 126
“Both insulin and metformin are considered safe for use in pregnancy, but can be associated with unwanted side effects such as gastrointestinal disturbances and hypoglycemia [52,53].”
BackgroundIjäs, H., Vääräsmäki, M., Saarela, T., Keravuo, R., & Raudaskoski, T. (2015) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12964 · Cited by 127
Hyperglycemia in pregnancy: prevalence, impact, and management challenges
Farrar, D. (2016) · International Journal of Women's Health · doi:10.2147/ijwh.s102117 · Cited by 129
Ma, R. C. W., Schmidt, M. I., Tam, W. H., McIntyre, H. D., & Catalano, P. M. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30278-9 · Cited by 125
Early Metformin in Gestational Diabetes: A Randomized Clinical Trial
Dunne, F., Newman, C., Alvarez-Iglesias, A., Ferguson, J., Smyth, A., Browne, M., O’Shea, P., Devane, D., Gillespie, P., Bogdanet, D., et al. (2023) · JAMA · doi:10.1001/jama.2023.19869 · Cited by 90
Egan, A. M., Dennedy, M. C., Al-Ramli, W., Heerey, A., Avalos, G., & Dunne, F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2684 · Cited by 125
“Only recently have convincing data suggesting the safety and efficacy of metformin emerged (29).”
BackgroundJiang, Y.-F., Chen, X.-Y., Ding, T., Wang, X.-F., Zhu, Z.-N., & Su, S.-W. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4403 · Cited by 124
12. Management of Diabetes in Pregnancy
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s015 · Cited by 152
“Randomized controlled trials support the efficacy and short-term safety of glyburide (11) (pregnancy category B) and metformin (12,13) (pregnancy category B) for the treatment of GDM.”
BackgroundBarry, J. A., Kay, A. R., Navaratnarajah, R., Iqbal, S., Bamfo, J. E. A. K., David, A. L., Hines, M., & Hardiman, P. J. (2010) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2010.485254 · Cited by 119
Farrar, D., Simmonds, M., Griffin, S., Duarte, A., Lawlor, D. A., Sculpher, M., Fairley, L., Golder, S., Tuffnell, D., Bland, M., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20860 · Cited by 117
Nachum, Z., Zafran, N., Salim, R., Hissin, N., Hasanein, J., Gam Ze Letova, Y., Suleiman, A., & Yefet, E. (2017) · Diabetes Care · doi:10.2337/dc16-2307 · Cited by 118
“Thus, glyburide might lead to fetal overgrowth and neonatal hypoglycemia through excessive fetal insulin secretion, whereas metformin increases insulin sensitivity in the target organswithout causing hyperinsulinism (2).”
BackgroundInfluentialAinuddin, J., Karim, N., Hasan, A. A., & Naqvi, S. A. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.10.001 · Cited by 119
“Similar results of good acceptability and cost effectiveness was found in other studies [17,18,34].”
BackgroundResultInfluentialThe mechanism of action of oral antidiabetic drugs: A review of recent literature
Bösenberg, L. H., & Zyl, D. G. V. (2008) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2008.10872177 · Cited by 144
“The use of metformin for gestational diabetes seems to be safe, as indicated by the recently published MiG study.(34)”
MethodMetformin compared with glyburide for the management of gestational diabetes
Silva, J. C., Pacheco, C., Bizato, J., de Souza, B. V., Ribeiro, T. E., & Bertini, A. M. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2010.04.028 · Cited by 115
“However, randomized controlled trials of glyburide [7,8] andmetformin [9,10] have reported neonatal results similar to or even better [11] than those observed following insulin treatment.”
BackgroundResultInfluentialSénat, M.-V., Affres, H., Letourneau, A., Coustols-Valat, M., Cazaubiel, M., Legardeur, H., Jacquier, J. F., Bourcigaux, N., Simon, E., Rod, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.4072 · Cited by 114
15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Brown, F. M., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s015 · Cited by 176
Lautatzis, M.-E., Goulis, D. G., & Vrontakis, M. (2013) · Metabolism · doi:10.1016/j.metabol.2013.06.006 · Cited by 113
Risk of pre‐eclampsia in women taking metformin: a systematic review and meta‐analysis
Alqudah, A., McKinley, M. C., McNally, R., Graham, U., Watson, C. J., Lyons, T. J., & McClements, L. (2018) · Diabetic Medicine · doi:10.1111/dme.13523 · Cited by 114
Štaud, F., Červený, L., & Čečková, M. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.716847 · Cited by 126
“In a recent randomized controlled open trial of 751 women with gestational diabetes, Rowan et al. (2008) evaluated the efficiency and safety of insulin versus metformin treatment.”
BackgroundResultThe management of gestational diabetes
Cheung, W. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3405 · Cited by 110
“72 It may be circumspect to await the fi ndings from this follow-up study before metformin can be considered safe for the routine treatment of GDM.”
Short‐ and long‐term outcomes of gestational diabetes and its treatment on fetal development
Murray, S. R., & Reynolds, R. M. (2020) · Prenatal Diagnosis · doi:10.1002/pd.5768 · Cited by 104
Guan, Y., Wang, D., Bu, H., Zhao, T., & Wang, H. (2020) · International Journal of Endocrinology · doi:10.1155/2020/5150684 · Cited by 106
“As the most widely used insulin sensitizer for PCOS, metformin can reduce liver glucose production, inhibit gluconeogenesis and adipogenesis, and improve peripheral tissue insulin sensitivity [44].”
BackgroundAinuddin, J. A., Karim, N., Zaheer, S., Ali, S. S., & Hasan, A. A. (2015) · Journal of Diabetes Research · doi:10.1155/2015/325851 · Cited by 108
“No differences in cesarean section and vaginal delivery rates were reported in other studies [7, 13, 15, 24].”
BackgroundResultInfluentialPoolsup, N., Suksomboon, N., & Amin, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109985 · Cited by 107
“Incidence of preterm births reported with metformin use in some of the studies were mostly at 33–35 week of gestation [20,23] which may be an acceptable risk comparing adverse outcomes of hyperglycemia during pregnancy especially in a situation e.”
BackgroundSivalingam, V. N., Myers, J., Nicholas, S., Balen, A. H., & Crosbie, E. J. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu037 · Cited by 108
“Metformin was well tolerated in all of the studies with around 2–7% unable to tolerate it (Rowan et al., 2008; Balani et al., 2009; Niromanesh et al., 2012).”
InfluentialDiabetes gestacional: um algoritmo de tratamento multidisciplinar
Weinert, L. S., Silveiro, S. P., Oppermann, M. L. D. R., Salazar, C. C., Simionato, B. M., Siebeneichler, A., & Reichelt, A. J. (2011) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302011000700002 · Cited by 147
“Peso normal (18,5-24,9) 11,5 – 16 0,42 (0,35-0,50)”
BackgroundInfluentialCharlton, R. A., Klungsøyr, K., Neville, A. J., Jordan, S., Pierini, A., de Jong-van den Berg, L. T. W., Bos, H. J., Puccini, A., Engeland, A., Gini, R., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0155737 · Cited by 106
Gestational diabetes mellitus: Who requires insulin therapy?: GDM: who requires insulin therapy?
WONG, V. W., & JALALUDIN, B. (2011) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2011.01329.x · Cited by 106
12. Management of Diabetes in Pregnancy
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s015 · Cited by 135
“Individual randomized controlled trials support the efficacy and short-term safety of metformin (19,20) (pregnancy category B) and glyburide (21) (pregnancy category B) for the treatment of GDM.”
Dodd, J. M., Louise, J., Deussen, A. R., Grivell, R. M., Dekker, G., McPhee, A. J., & Hague, W. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30310-3 · Cited by 99
Self-citationCésar, M. J. P., Molina‐Vega, M., Suárez-Arana, M., González‐Mesa, E., Sola-Moyano, A. P., Roldan-López, R., Romero-Narbona, F., Olveira, G., Tinahones, F. J., & González‐Romero, S. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.229 · Cited by 112
Exercise guidelines for gestational diabetes mellitus
Padayachee, C., & Coombes, J. S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i8.1033 · Cited by 138
A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes
Barbour, L. A., Scifres, C., Valent, A. M., Friedman, J. E., Buchanan, T. A., Coustan, D., Aagaard, K., Thornburg, K. L., Catalano, P. M., Galan, H. L., et al. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.06.013 · Cited by 101
Diabetes in pregnancy outcomes: A systematic review and proposed codification of definitions
The International Association of Diabetes in Pregnancy Study Group (IADPSG) Working Group on Outcome Definitions, Feig, D. S., Corcoy, R., Jensen, D. M., Kautzky‐Willer, A., Nolan, C. J., Oats, J. J. N., Sacks, D. A., Caimari, F., & McIntyre, H. D. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2640 · Cited by 100
Urbaniak, S. K., Boguszewska, K., Szewczuk, M., Kaźmierczak-Barańska, J., & Karwowski, B. T. (2020) · Molecules · doi:10.3390/molecules25010202 · Cited by 112
“However, this option is only recommended for pregnant women who strggle to maintain the right glucose concentration level [80].”
BackgroundPregnancy in cystic fibrosis: Review of the literature and expert recommendations
Jain, R., Kazmerski, T. M., Zuckerwise, L. C., West, N. E., Montemayor, K., Aitken, M. L., Cheng, E., Roe, A. H., Wilson, A. W. M., Mann, C., et al. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.07.019 · Cited by 114
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Drummond, R. F., Seif, K. E., & Reece, E. A. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.08.024 · Cited by 113
Metformin for gestational diabetes in routine clinical practice
Goh, J. E. L., Sadler, L., & Rowan, J. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03361.x · Cited by 99
Self-citationGlycemia and Its Relationship to Outcomes in the Metformin in Gestational Diabetes Trial
Rowan, J. A., Gao, W., Hague, W. M., & McIntyre, H. D. (2010) · Diabetes Care · doi:10.2337/dc09-1407 · Cited by 96
“The methodology and outcomes have been published previously (10).”
MethodSelf-citationMechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Correia, S., Carvalho, C., Santos, M., Seica, R., Oliveira, C., & Moreira, P. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708786369546 · Cited by 96
“It has also been shown that in women with gestational diabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin [39].”
BackgroundTieu, J., Middleton, P., McPhee, A. J., & Crowther, C. A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007222.pub2 · Cited by 94
Wouldes, T. A., Battin, M., Coat, S., Rush, E. C., Hague, W. M., & Rowan, J. A. (2016) · Archives of Disease in Childhood - Fetal and Neonatal Edition · doi:10.1136/archdischild-2015-309602 · Cited by 95
Self-citationOral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes
Brown, J., Martis, R., Hughes, B., Rowan, J., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011967.pub2 · Cited by 95
Self-citationTsakiridis, I., Giouleka, S., Mamopoulos, A., Kourtis, A., Athanasiadis, A., Filopoulou, D., & Dagklis, T. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000899 · Cited by 94
“04) than insulin.(55) Of note, no differences in congenital anomalies or serious perinatal outcomes were identified in the 2 groups.”
BackgroundSMFM statement: pharmacological treatment of gestational diabetes
(2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.01.041 · Cited by 94
Tertti, K., Ekblad, U., Vahlberg, T., & Rönnemaa, T. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.95 · Cited by 91
“It turned out that treatment with metformin fell within the preset condition of being less than 10% worse than with insulin [20].”
BackgroundResultInfluentialNguyen, D., Hsu Jean, W., Jahoor, F., & Sekhar Rajagopal, V (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2376 · Cited by 93
Kalafat, E., Sukur, Y. E., Abdi, A., Thilaganathan, B., & Khalil, A. A. (2018) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.19084 · Cited by 100
Weight gain adequacy and pregnancy outcomes in gestational diabetes: a meta‐analysis
Viecceli, C., Remonti, L. R., Hirakata, V. N., Mastella, L. S., Gnielka, V., Oppermann, M. L. R., Silveiro, S. P., & Reichelt, A. J. (2017) · Obesity Reviews · doi:10.1111/obr.12521 · Cited by 90
“5 kg lower gain after treatment was found in the metformin group, even when supplementary insulin was used (65).”
MethodMcCance, D. R. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.07.009 · Cited by 107
A review of current treatment strategies for gestational diabetes mellitus
Kelley, K., Carroll, D., & Meyer, A. (2015) · Drugs in Context · doi:10.7573/dic.212282 · Cited by 88
“There were no significant differences in the primary composite outcome (neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute APGAR <7, and premature delivery [<37 weeks]) between metformin and insulin [29].”
BackgroundInfluentialMetformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study
Brand, K. M. G., Saarelainen, L., Sõnajalg, J., Boutmy, E., Foch, C., Vääräsmäki, M., Morin-Papunen, L. C., Schlachter, J., CLUE Study Group, Hakkarainen, K. M., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002363 · Cited by 110
The maternal and fetal impacts of obesity and gestational diabetes on pregnancy outcome
Dennedy, M. C., & Dunne, F. (2010) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.06.001 · Cited by 88
Diabetes in pregnancy: health risks and management
Ali, S., & Dornhorst, A. (2011) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.109157 · Cited by 89
“Although the ADA currently does not recommend the use of metformin it does for glibenclamide,(5) while NICE supports the use of both(3) following results of two randomised control trials.(95) 96”
BackgroundSouth Asian women with diabetes: Psychosocial challenges and management: Consensus statement
Bajaj, S., Jawad, F., Islam, N., Mahtab, H., Bhattarai, J., Shrestha, D., Wijeyaratne, C. N., Muthukuda, D. T., Widanage, N. W., Aye, T. T., et al. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.113720 · Cited by 107
“[51] Regular Human Insulin, long acting Neutral Protamine Hagedorn (NPH) and detemir insulin have been proven to be safe in pregnancy.”
Gestationsdiabetes (GDM) (Update 2023)
Kautzky‐Willer, A., Winhofer, Y., Kiss, H., Falcone, V., Berger, A., Lechleitner, M., Weitgasser, R., & Harreiter, J. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02181-9 · Cited by 113
“Schwangerschaftswoche wurde eine niedrigere Rate schwerer neonataler Hypoglykämien, jedoch eine höhere Frühgeburtenrate beobachtet [40].”
BackgroundCicero, A. F. G., Tartagni, E., & Ertek, S. (2012) · Archives of Medical Science · doi:10.5114/aoms.2012.31622 · Cited by 81
“[49] studied 751 women at 20-33 weeks of pregnancy with gestational diabetes during the MiG trial (Metformin versus Insulin for the treatment of Gestational diabetes).”
Ashoush, S., El‐Said, M., Fathi, H., & Abdelnaby, M. (2016) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.12950 · Cited by 80
Shpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Hirst, J. E., Tran, T. S., Do, M. A. T., Rowena, F., Morris, J. M., & Jeffery, H. E. (2012) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-12-81 · Cited by 81
“Given the encouraging evidence of the safety and efficacy of metformin in the management of women with GDM [32], it is possible that this could provide a safer method of glycaemic control for women in Vietnam and other low resource settings in the future.”
Wexler, D. J., Powe, C. E., Barbour, L. A., Buchanan, T., Coustan, D. R., Corcoy, R., Damm, P., Dunne, F., Feig, D. S., Ferrara, A., et al. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002726 · Cited by 80
Self-citationMetformin in Pregnancy: Mechanisms and Clinical Applications
Hyer, S., Balani, J., & Shehata, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071954 · Cited by 78
Metformin in the management of diabetes during pregnancy and lactation
Priya, G., & Kalra, S. (2018) · Drugs in Context · doi:10.7573/dic.212523 · Cited by 99
Gestationsdiabetes (GDM) (Update 2019)
Kautzky-Willer, A., Harreiter, J., Winhofer-Stöckl, Y., Bancher-Todesca, D., Berger, A., Repa, A., Lechleitner, M., & Weitgasser, R. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1419-8 · Cited by 73
ADIPS 2020 guideline for pre‐existing diabetes and pregnancy
Rudland, V. L., Price, S., Hughes, R. C. E., Barrett, H. L., Lagstrom, J., Porter, C., Britten, F. L., Glastras, S. J., Fulcher, I., Wein, P., et al. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13265 · Cited by 87
Gestational Diabetes Mellitus Is Associated with Altered Neutrophil Activity
Stoikou, M., Grimolizzi, F., Giaglis, S., Schäfer, G., van Breda, S. V., Hoesli, I. M., Lapaire, O., Huhn, E. A., Hasler, P., Rossi, S. W., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00702 · Cited by 83
Mesdaghinia, E., Samimi, M., Homaei, Z., Saberi, F., Moosavi, S. G. A., & Yaribakht, M. (2013) · PubMed Central · Cited by 107
Metformin versus insulin for gestational diabetes: a systematic review and meta-analysis
Bao, L.-X., Shi, W., & Han, Y. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2019.1670804 · Cited by 82
“Glucose targets seemed to reach sooner in the metformin group [14,17,23].”
BackgroundMetformin - A convenient alternative to insulin for Indian women with diabetes in pregnancy
Rai, L., Meenakshi, D., & Kamath, A. (2009) · Indian Journal of Medical Sciences · doi:10.4103/0019-5359.58878 · Cited by 75
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Controversies in gestational diabetes
Nolan, C. J. (2010) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.004 · Cited by 96
The use of glyburide in the management of gestational diabetes mellitus: A meta-analysis
Zeng, Y.-C., Li, M.-J., Chen, Y., Jiang, L., Wang, S.-M., Mo, X.-L., & Li, B.-Y. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.03.001 · Cited by 76
Han, C. S., Herrin, M. A., Pitruzzello, M. C., Mulla, M. J., Werner, E. F., Pettker, C. M., Flannery, C. A., & Abrahams, V. M. (2014) · American Journal of Reproductive Immunology · doi:10.1111/aji.12339 · Cited by 83
Wackernagel, D., Gustafsson, A., Bonamy, A. E., Reims, A., Ahlsson, F., Elfving, M., Domellöf, M., & Hansen‐Pupp, I. (2019) · Acta Paediatrica · doi:10.1111/apa.14955 · Cited by 82
A Review of the Pathophysiology and Management of Diabetes in Pregnancy
Egan, A. M., Dow, M. L., & Vella, A. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.02.019 · Cited by 67
“Metformin, a biguanide and glyburide (glibenclamide), a sulphonylurea have been studied and used with good effect during pregnancy.(84,85) Metformin transfers to the fetus with high fetal-to-maternal ratios.”
BackgroundTarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003126 · Cited by 73
“The majority of studies randomised women between 20 and 36 weeks of gestation [31,32,34,42,43,44,48,49,50,51,52,53,54,58], although others [36– 39,55] randomised women between 11 and 33 weeks of gestation.”
BackgroundMethodResultInfluentialComparison of glyburide and insulin in the management of gestational diabetes: a meta-analysis
Song, R., Chen, L., Chen, Y., Si, X., Liu, Y., Liu, Y., Irwin, D. M., & Feng, W. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182488 · Cited by 73
Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety
Nicholson, W., & Baptiste-Roberts, K. (2011) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2010.10.018 · Cited by 72
Cheng, Y. W., Chung, J. H., Block-Kurbisch, I., Inturrisi, M., & Caughey, A. B. (2012) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2011.580402 · Cited by 72
Ghomian, N., Vahed, S. H. M., Firouz, S., Yaghoubi, M. A., Mohebbi, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27238 · Cited by 77
“Positive history for gestational diabetes 34 (24) 29 (20) 0.”
BackgroundInfluentialGestational diabetes mellitus: challenges in diagnosis and management
Mpondo, B. C. T., Ernest, A. I., & Dee, H. E. (2015) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/s40200-015-0169-7 · Cited by 85
“In a randomized controlled trial involving women with GDM, the use of metformin, whether alone or with supplemental insulin, was not associated with increased perinatal complications compared to insulin alone [49].”
BackgroundTarry‐Adkins, J. L., Ozanne, S. E., & Aiken, C. (2021) · Scientific Reports · doi:10.1038/s41598-021-88650-5 · Cited by 84
Gestational diabetes: Implications for fetal growth, intervention timing, and treatment options
Mirabelli, M., CHIEFARI, E. D., Tocci, V., Greco, E. A., FOTI, D. P., & Brunetti, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.06.003 · Cited by 75
Farrar, D., Tuffnell, D. J., & West, J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005542.pub2 · Cited by 69
Feng, Y., & Yang, H. (2017) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1228061 · Cited by 68
“Our study found that insulin caused more neonates hypoglycemia compared with metformin, although metformin crosses the placenta [14].”
BackgroundChanging trends in management of gestational diabetes mellitus
Poomalar, G. K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.284 · Cited by 68
Simmons, D., Hague, W. M., Teede, H. J., Cheung, N. W., Hibbert, E. J., Nolan, C. J., Peek, M. J., Girosi, F., Cowell, C. T., Wong, V. W., et al. (2018) · Medical Journal of Australia · doi:10.5694/mja17.01129 · Cited by 67
Self-citationLi, X.-J., Yu, Y.-X., Liu, C.-Q., Zhang, W., Zhang, H.-J., Yan, B., Wang, L.-Y., Yang, S.-Y., & Zhang, S.-H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03917.x · Cited by 67
Metformin from mother to unborn child-are there unwarranted effects?
Nguyen, L., Chan, S.-Y., & Teo, A. K. K. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.047 · Cited by 67
“A large randomised controlled trial (RCT) of 751 women raised concerns that metformin might increase the rate of premature delivery but the study did not find any other significant difference in pregnancy outcomes between themetformin and control groups [60].”
BackgroundGeorge, A., Mathews, J. E., Sam, D., Beck, M., Benjamin, S. J., Abraham, A., Antonisamy, B., Jana, A. K., & Thomas, N. (2015) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12276 · Cited by 68
Gestational diabetes mellitus--Indian guidelines.
Seshiah, V., Sahay, B. K., Das, A. K., Shah, S. N., Banerjee, S., Rao, P. V., Ammini, A. C., Balaji, V., Gupta, S., Divakar, H., et al. (2009) · PubMed · Cited by 78
Updates in Gestational Diabetes Prevalence, Treatment, and Health Policy
Dickens, L. T., & Thomas, C. C. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1147-0 · Cited by 83
Khunti, K., Kumar, S., & Brodie, J. (2009) · Cited by 108
on behalf of the MiTy Collaborative Group, Feig, D. S., Murphy, K., Asztalos, E., Tomlinson, G., Sanchez, J., Zinman, B., Ohlsson, A., Ryan, E. A., Fantus, I. G., et al. (2016) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-016-0954-4 · Cited by 65
“It has been postulated that a reduction in weight gain with metformin treatment may be due to decreased appetite, and a reduction in hyperinsulinemia associated with reduced insulin resistance [22].”
Landi, S. N., Radke, S., Engel, S. M., Boggess, K., Stürmer, T., Howe, A. S., & Funk, M. J. (2019) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2018.4214 · Cited by 64
Ellerbrock, J., Spaanderman, B., van Drongelen, J., Mulder, E., van Balen, V. A. L., Schiffer, V. M. M. M., Jorissen, L. M., Alers, R., Leenen, J., Ghossein‐Doha, C., et al. (2022) · Nutrients · doi:10.3390/nu14122444 · Cited by 75
“Studies about the safety and efficacy of metformin in GDM show that metformin is associated with a lower risk of gestational hypertension, pre-eclampsia, macrosomia, and neonatal hypoglycemia compared with insulin therapy [22–24], even though the glycemic control profiles are found to be comparable [25,26].”
BackgroundMaternal serum adiponectin multimers in gestational diabetes
Mazaki-Tovi, S., Romero, R., Vaisbuch, E., Erez, O., Mittal, P., Chaiworapongsa, T., Kim, S. K., Pacora, P., Yeo, L., Gotsch, F., et al. (2009) · jpme · doi:10.1515/jpm.2009.101 · Cited by 65
Metadata
- Authors
- Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P.
- Affiliations
- Auckland City Hospital (NZ)
- Women's and Children's Hospital (AU)
- Auckland University of Technology (NZ)
- University of Auckland (NZ)
- Christchurch Hospital (NZ)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-08
- Volume
- 358
- Issue
- 19
- Pages
- 2003-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003621575
- Cited by
- 1,291
- References
- 33
- Citations by year
- 2026: 49 · 2025: 60 · 2024: 52 · 2023: 65 · 2022: 63 · 2021: 90 · 2020: 67 · 2019: 66 · 2018: 105 · 2017: 125 · 2016: 68 · 2015: 82 · 2014: 69 · 2013: 62 · 2012: 56
- FWCI
- 78.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, insulin, gestational diabetes mellitus, neonatal hypoglycemia, perinatal complications, maternal glycemic control, postpartum glucose tolerance, treatment acceptability, treatment preferences, neonatal respiratory distress, phototherapy
- MeSH terms
- Adult, Drug Therapy, Combination, Female, Gestational Age, Humans, Hypoglycemia, Hypoglycemic Agents, Infant, Newborn, Insulin, Jaundice, Neonatal, Metformin, Pregnancy, Pregnancy Complications, Cardiovascular, Pregnancy Outcome, Diabetes, Gestational, Patient Satisfaction, Premature Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.